BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.
This appointment is significant as BioStem, a company focused on placental-derived products for advanced wound care, undertakes a business expansion beyond chronic wound care and plans to raise its profile in the public markets in 2026. Ungrodt's twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory expertise, is expected to strengthen board governance during this pivotal growth phase. As Audit Committee Chair, she will oversee the company's financial reporting, internal controls and risk management practices.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's experience will make a terrific addition to the board. Ungrodt expressed excitement about joining at this pivotal time, noting BioStem's strong momentum in the chronic wound market and its recent expansion into acute applications of its technologies. She highlighted the company's potential to improve patient outcomes as it continues to scale and innovate.
Ungrodt's prior experience includes serving as Chair of the Audit Committee for Feeding San Diego and as an Advisory Board Member for Life Science Cares. During her tenure at EY, she served more than 70 companies across the Life Sciences sector. She holds a BS in Accounting from San Diego State University and is a Certified Public Accountant. Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025. Poe served on BioStem's Board of Directors for three years before joining the organization.
BioStem is an emerging leader in placental and umbilical cord-derived tissue products used by clinicians across various medical specialties. The company's proprietary allograft portfolio is derived from donated birth tissue, and its proprietary processes are designed to preserve the tissue's natural properties. BioStem continues to conduct research to expand the scientific understanding of placental-derived tissue products and to bring new products to market. The company's quality management system is accredited by the American Association of Tissue Banks, and its procedures comply with current Good Tissue Practices and current Good Manufacturing Processes. More information about the company is available at https://www.biostemtechnologies.com.
